Petition Closed

The availability of these drugs donepezil; rivastigmine; galantamine; and memantine are vital to people suffering from dementia and Alzheimer's disease. They are specifically designed for dementia to slow down progression of the disease, as well as ease symptoms. If these drugs are removed from the Pharmaceutical Benefits Scheme (PBS) it will make it very expensive (up to $150 a month) for people to access these medications. We need to be a voice for those unable to speak and keep these medications on the PBS.

Letter to
The Pharmaceutical Benefits Advisory Committee
I just signed the following petition addressed to: The Pharmaceutical Benefits Advisory Committee.

----------------
Keep dementia drugs on the PBS

The availability of these drugs donepezil; rivastigmine; galantamine; and memantine are vital to people suffering from dementia and Alzheimer's disease. They are specifically designed for dementia to slow down progression of the disease, as well as ease symptoms.

If these drugs are removed from the Pharmaceutical Benefits Scheme (PBS) it will make it very expensive (up to $150 a month) for people to access these medications. This will add undue stress to an already very stressful situation.

With the availability of dementia care beds in nursing homes and hospitals at critically low levels, it makes more sense to keep these drugs available on PBS so these patients can stay out of high level care for longer.

We need to be a voice for those unable to speak and keep these medications on the PBS.
----------------

Sincerely,

Kerri Cross